Moderna Revenue and Competitors
Estimated Revenue & Valuation
- Moderna's estimated annual revenue is currently $11.8B per year.
- Moderna's estimated revenue per employee is $1,473,225
- Moderna's total funding is $2.7B.
- Moderna's current valuation is $83B. (January 2022)
Employee Data
- Moderna has 8030 Employees.
- Moderna grew their employee count by 26% last year.
Moderna's People
Name | Title | Email/Phone |
---|---|---|
1 | Principal Product Owner, SAP Order to Cash | Reveal Email/Phone |
2 | Director, Business Process Owner (AP/T&E) | Reveal Email/Phone |
3 | Executive Director, Business Development & Corporate Strategy | Reveal Email/Phone |
4 | Sr Specialist ERP and CMO Reconciliation | Reveal Email/Phone |
5 | Chief Staff, Research and Early Development | Reveal Email/Phone |
6 | CMO Operations | Reveal Email/Phone |
7 | CSO, External Research Ventures (XRV) | Reveal Email/Phone |
8 | Chief Architect, VP | Reveal Email/Phone |
9 | Chief Staff, Director Corporate Security Operations | Reveal Email/Phone |
10 | CMO Operations Lead Moderna Italy | Reveal Email/Phone |
Moderna Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Moderna?
Moderna is a leader in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body?s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. With its breakthrough platform, Moderna is creating mRNA medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets or underserved areas of medical need. Moderna is developing its innovative mRNA medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases, through solely controlled programs and collaborations with strategic partners. Headquartered in Cambridge, Mass., privately held Moderna currently has strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc (MRK) and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation. In 2017 Moderna was ranked a top biopharma industry employer by Science Magazine and a Top Place to Work by the Boston Globe. To learn more, visit www.modernatx.com.
keywords:N/A$2.7B
Total Funding
8030
Number of Employees
$11.8B
Revenue (est)
26%
Employee Growth %
$83B
Valuation
N/A
Accelerator
Moderna News
The University of Virginia recently tracked its COVID-vaccinated employees who wanted to participate in a study, then monitored the...
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Poland can reach a compromise with Moderna on increasing the flexibility of COVID-19 vaccine contracts, the health minister said on Friday,...
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Swissmedic has authorized a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 µg dose level in particularly vulnerable individuals 12 years of ...
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that a booster dose of Spikevax, the Company’s vaccine ag ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1967.3M | 9691 | 6% | N/A |
#2 | $3400M | 9784 | 6% | $35M |
#3 | $11100M | 10056 | -10% | N/A |
#4 | $3904M | 10328 | N/A | N/A |
#5 | $1180M | 10407 | 6% | $100.5M |